Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor.Pfizer (PFE -0.20%) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable ...

Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.The past few years have been tough ones for investors holding shares of Pfizer (PFE 1.26%). The Big Pharma stock is down by more than half from the peak it set in late 2021.Pfizer's stock price was hammered, but that didn't prevent the company from meeting and raising its dividend commitment. Last December, the pharmaceutical company raised its payout for the 15th consecutive year.Shares of Pfizer offer an eye-popping 6 ...

Pfizer TodayPFEPfizer$28.22 +0.24 (+0.86%) 52-Week Range$25.20▼$37.80Dividend Yield5.95%Price Target$35.54Add to WatchlistPharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender. Pfizer operates in the medical sector. In addition to the incu ...

Pfizer's valuation looks attractive, but that doesn't mean the stock is a lock to outperform the broader market.Pfizer (PFE 0.86%) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%.The shares' t ...

Alexandros Michailidis In the last few years, I covered several pharmaceutical companies - including Gilead Sciences, Inc. (GILD), Novo Nordisk A/S (NVO) or Eli Lilly and Company (LLY) - and wrote in one way or another about many different pharmaceutical companies. But one major pharmaceutical company I never wrote about is Pfizer Inc. (NYSE:PFE). The company is one of the oldest and major pharmaceutical companies in the world and among the top 10 pharmaceutical companies (according to market capitalization ...

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for their Omicron JN.1-adapted monovalent COVID-19 vaccine.The CHMP has recommended the approval of Comirnaty JN.1, the Omicron JN.1-adapted monovalent COVID-19 vaccine, for active immunization against the COVID-19 virus in individuals aged six months and above.The decision was based on the recommendation from the World Health ...

In this articlePFEKena Betancur | Corbis News | Getty ImagesPfizer had a "phenomenal" first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant's stock had closed 6% higher after its quarterly results topped analyst estimates and it hiked its full-year outlook. It was a far cry from the year prior, when Pfizer's shares plunged more than 40%, making it one ...

These top healthcare stocks are no-brainer buys in 2024 and beyond.This latest bull market is seeing a wave of enthusiasm from investors ... for the stocks of select companies. While some stocks are getting enthusiastic buy-in, there are plenty of others that haven't quite joined in on the market frenzy.When you're investing in stocks with a long-term mindset around a quality company's ability to execute a business plan, you can afford to be patient and eventually benefit from the growth stories it generate ...

One of the pharma giant's top-selling products is about to face some intense competition.It's no secret why Pfizer (PFE -0.82%) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and pill. It's also facing patent cliffs for many of its top drugs. That's why even though it's trading at a seemingly cheap 12 times its estimated future earnings, investors aren't piling into the stock. And now, one of its riv ...

One company's negative results can increase scrutiny of another's work.When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (PFE -0.86%) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd be logical to assume that shares of Sarepta Therapeutics, (SRPT -1.64%) a biotech focused on developing DMD drugs, would then rise.But that didn't happen -- at least not until Sare ...